Wells Fargo Calls Boston Scientific’s WATCHMAN Trial “Good, Not Great”

Wells Fargo says Boston Scientific’s CHAMPION-AF trial met all endpoints for WATCHMAN FLX but calls results “good, not great” due to slightly higher stroke rate vs blood thinners.